Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
Omotola Olasupo/LinkedIn
Jan 20, 2026, 13:25

Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada

RPTH Journal shared on LinkedIn:

”Comparative safety of hemophilia therapies in Canada

Real-world comparative safety data for hemophilia therapies remain limited.

This study leverages national registry data to better understand adverse drug reactions across commonly used treatments using Canadian registry data over 5 years

  • Allergic reactions were the most frequently reported adverse drug reactions
  • A higher number of reported events was observed with emicizumab, although novelty bias cannot be excluded
  • No inhibitor development was reported with emicizumab or bypassing agents

These findings provide important real-world insights into the relative safety of therapies used in hemophilia A and B, while highlighting the need for continued pharmacovigilance as treatment landscapes evolve.”

Read the full article here.

Article: Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study

Authors: Omotola Olasupo, Emma Iserman, Arun Keepanasseril, Quazi Ibrahim, Zainab Salim Ali Al-Housni, Federico Germini, Jean-Eric Tarride, Lawrence Mbuagbaw, Shannon Jackson, Ingrid Blydt-Hansen, Michelle Bech, Celina Woo, Mark Belletrutti, Alfonso Iorio, Davide Matino:  the Association of Hemophilia Clinic Directors of Canada (AHCDC)

Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada

Stay updated on all scientific advances with Hemostasis Today.

bleeding disorders Canada Emicizumab Headlines Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Omotola Olasupo RPTH Journal
NewsFeed